ADMA Biologics (ADMA)
(Delayed Data from NSDQ)
$19.33 USD
+0.63 (3.37%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $19.32 -0.01 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ADMA 19.33 +0.63(3.37%)
Will ADMA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADMA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADMA
Adma Biologics (ADMA) Ascends While Market Falls: Some Facts to Note
Adma Biologics (ADMA) Rises As Market Takes a Dip: Key Facts
ADMA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Brokers Suggest Investing in Adma Biologics (ADMA): Read This Before Placing a Bet
Adma Biologics (ADMA) Exceeds Market Returns: Some Facts to Consider
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Other News for ADMA
ADMA Biologics Shares Cross Above 200 DMA
ADMA Biologics to Report Second Quarter 2025 Financial Results on August 6, 2025 | ADMA Stock News
ADMA Biologics Inc (ADMA) Announces Q2 2025 Financial Results Conference Call | ADMA stock news
Is ADMA Biologics Gaining or Losing Market Support?
Calamos Timpani Small Cap Growth Fund Q1 2025 Commentary